NCT07640750Not yet recruiting
Efficacy of Asciminib in Real-world in Patients With Chronic Myeloid Leukemia in Second or Subsequent Lines
Retrospective and Prospective Observational Study on the Efficacy and Tolerability of Asciminib in Real-world Clinical Practice in Patients With Chronic Myeloid Leukemia Treated in Second or Subsequent Lines: ASCIRLI (ASCIminib in Real-Life Italy)
Source: ClinicalTrials.gov · Last updated 11 Jun 2026
Brief summary (registry, in English)
The goal of this observational study is to evaluate the efficacy and tolerability of asciminib in real-life in patients with chronic myeloid leukemia treated in second or subsequent lines. The main object of the study is to assess the achievement of Major Molecular Response.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 98 (estimated)
- First submitted
- 1 Jun 2026
- Start date
- Sept 2026
- Primary completion date
- Sept 2031
- Lead sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
- Diseases
- Chronic myeloid leukaemia
- NCT number
- NCT07640750
What you commit to
- Study type: Observational
- Planned participants: 98
- From Sept 2026 to the primary completion date, Sept 2031
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- None
Who the study is looking for
- Patients aged ≥ 18 years and no upper age limit;
- Patients with a diagnosis of CML-CP who started treatment with asciminib according to clinical practice - from the date of commercial availability of asciminib - until the end of recruitment period (two years after the first patient included);
- Patients treated with asciminib in second or subsequent lines of therapy (≥2L)
- Patients who provide written informed consent to participate in the study (if applicable).
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.